Sample Page
Author:
Femasys Inc.
Posted Date:
May 11, 2026
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
Femasys Inc.
May 11, 2026
Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete
Femasys Inc.
May 7, 2026
Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete
Femasys Inc.
May 7, 2026
Femasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026
Femasys Inc.
April 24, 2026
Femasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026
Femasys Inc.
April 24, 2026
Femasys Drives International Growth with Israeli Market Entry for Fertility Portfolio
Femasys Inc.
April 16, 2026
Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth
Femasys Inc.
April 1, 2026
Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update
Femasys Inc.
April 1, 2026
Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors
Femasys Inc.
March 18, 2026
Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment
Femasys Inc.
March 10, 2026
1
2
Next
